Phibro Animal Health (PAHC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 Sep, 2026Executive summary
Annual Meeting scheduled for November 3, 2026, at the company's Teaneck, NJ offices.
Shareholders of record as of September 11, 2026, are eligible to vote.
Proxy materials are primarily distributed online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of three Class I Directors: Daniel M. Bendheim, Jonathan Bendheim, and Sam Gejdenson, to serve until the 2029 Annual Meeting.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending June 30, 2027.
Board recommends voting FOR all director nominees and FOR auditor ratification.
Proxies may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends all three Class I Director nominees for election.
Directors to serve three-year terms, expiring at the 2029 Annual Meeting.
Latest events from Phibro Animal Health
- Shareholders will vote on director elections and auditor ratification amid strong FY 2026 results.PAHC
Proxy filing - Record sales and profit growth in FY26, with continued expansion expected in FY27.PAHC
Q4 2026 - Acquisition-driven growth and innovation are strengthening margins and expanding global reach.PAHC
Stifel Jaws & Paws Conference 2025 - Strong growth, innovation, and sustainability initiatives position the business for continued expansion.PAHC
Stifel 2026 Jaws & Paws Conference - Broad-based growth, new sustainability platform, and regulatory adaptation drive future outlook.PAHC
Bank of America Global Healthcare Conference 2026 - Q3 sales up 10% to $383.5M, with strong Animal Health growth and upgraded FY2026 guidance.PAHC
Q3 2026 - Strong growth, successful integration, and strategic continuity define the outlook.PAHC
BofA Securities Animal Health Summit - Net sales up 21% and EBITDA up 41%, prompting a raised outlook amid strong Animal Health growth.PAHC
Q2 2026 - Animal Health growth and Zoetis acquisition drive optimism despite lower net income.PAHC
Q4 2024